{"disease":{"id":"proliferative-nephritis","name":"proliferative nephritis"},"drugs":{"marketed":[{"drug_id":"prednison","indication_name":"Diffuse Proliferative Lupus Nephritis","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":null,"generic_name":"prednison","company_name":"Wen Zhang","drug_phase":"marketed","molecular_target":"Annexin A1, Sodium/nucleoside cotransporter 1, Glucocorticoid receptor","drug_class":"","quality_score":19,"revenue":null,"mechanism":null},{"drug_id":"prednisone","indication_name":"Diffuse Proliferative Lupus Nephritis","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":"Deltasone","generic_name":"prednisone","company_name":"Generic (originally Schering)","drug_phase":"marketed","molecular_target":"Annexin A1, Sodium/nucleoside cotransporter 1, Glucocorticoid receptor","drug_class":"Corticosteroid [EPC]","quality_score":40,"revenue":null,"mechanism":""}],"pipeline":[],"offLabel":[],"totalMarketed":2,"totalPipeline":0},"trials":{"data":[{"nct_id":"NCT06065852","title":"National Registry of Rare Kidney Diseases","phase":"","overall_status":"RECRUITING","enrollment_count":35000,"lead_sponsor_name":"UK Kidney Association","has_results":false},{"nct_id":"NCT03955445","title":"Long-term Efficacy, Safety and Tolerability of Iptacopan in C3G or IC-MPGN","phase":"PHASE3","overall_status":"RECRUITING","enrollment_count":225,"lead_sponsor_name":"Novartis Pharmaceuticals","has_results":false},{"nct_id":"NCT05067127","title":"Phase III Study Assessing the Efficacy and Safety of Pegcetacoplan in Patients With C3 Glomerulopathy or Immune-Complex Membranoproliferative Glomerulonephritis","phase":"PHASE3","overall_status":"COMPLETED","enrollment_count":124,"lead_sponsor_name":"Apellis Pharmaceuticals, Inc.","has_results":true},{"nct_id":"NCT03687905","title":"Proliferative Lupus Nephritis Treatment With Chloroquine and Hydroxychloroquine","phase":"","overall_status":"UNKNOWN","enrollment_count":60,"lead_sponsor_name":"Tanta University","has_results":false},{"nct_id":"NCT07389499","title":"A Clinical Study Evaluating the Safety and Efficacy of GT719 Universal Cell Injection in the Treatment of Immune-mediated Kidney Diseases","phase":"EARLY_PHASE1","overall_status":"RECRUITING","enrollment_count":30,"lead_sponsor_name":"Grit Biotechnology","has_results":false},{"nct_id":"NCT03459443","title":"A Proof of Concept Study for a 12 Month Treatment in Patients With C3G or IC-MPGN Treated With ACH-0144471","phase":"PHASE2","overall_status":"TERMINATED","enrollment_count":22,"lead_sponsor_name":"Alexion Pharmaceuticals, Inc.","has_results":true},{"nct_id":"NCT03095118","title":"Daratumumab in Treatment of PGNMID and C3 GN","phase":"PHASE2","overall_status":"COMPLETED","enrollment_count":12,"lead_sponsor_name":"Fernando Fervenza","has_results":true},{"nct_id":"NCT07111338","title":"Telitacicept for PGNMID: A Single-Arm Study","phase":"PHASE2","overall_status":"ACTIVE_NOT_RECRUITING","enrollment_count":10,"lead_sponsor_name":"Peking University First Hospital","has_results":false},{"nct_id":"NCT03723512","title":"Non-contrast Enhanced MRI in Patients With C3 Glomerulopathy (C3G) or Immune-complex Membranoproliferative Glomerulonephritis (IC-MPGN) Enrolled in the ACH471-205 Study","phase":"NA","overall_status":"COMPLETED","enrollment_count":7,"lead_sponsor_name":"Mario Negri Institute for Pharmacological Research","has_results":false},{"nct_id":"NCT03124368","title":"A Proof-of-Mechanism Study to Determine the Effect of Danicopan on C3 Levels in Participants With C3G or IC-MPGN","phase":"PHASE2","overall_status":"COMPLETED","enrollment_count":6,"lead_sponsor_name":"Alexion Pharmaceuticals, Inc.","has_results":true},{"nct_id":"NCT04729062","title":"C3G/Primary IC-MPGN EAP","phase":"","overall_status":"APPROVED_FOR_MARKETING","enrollment_count":null,"lead_sponsor_name":"Apellis Pharmaceuticals, Inc.","has_results":false}],"total":11},"guidelines":[],"source":"Drug Landscape verified database"}